Drug Safety and PV Services

When patient safety is of the utmost importance, Sponsors trust MMS as their go-to CRO.

We are very impressed with the quality of the MMS deliverables. Excellent improvement proposals!
Oncology Clinical Lead
Top 5 Pharma

MMS provides comprehensive solutions to meet the pharmacovigilance and drug safety needs of the pharmaceutical industry today. An efficient, adaptable model enables increased productivity, enhances safety monitoring external reporting, and offers Sponsors more time to focus on strategy rather than day-to-day processing activities.

Comprehensive safety services across all phases of clinical research include:

  • Implementation and Management of safety databases, including data migration services
  • Medical safety monitoring
  • 24/7 case management
  • Serious Adverse Event (SAE) management and expedited reporting
  • Ad hoc safety analyses and risk management
  • Signal detection
  • Annual reports, periodic safety update reports (PSURs), and expert reports
  • Labeling/CCDS support
  • Literature reviews

Medical Monitoring Services
Medical monitoring experts at MMS provide medical reviews and oversight of clinical trial activities across all phases of clinical research, including first-in-human trials. Experienced medical staff bring a practical and real-world clinical perspective to assist study and sponsor teams with every aspect of subject safety. This includes ongoing collaboration with clinical trial investigators, assisting with safety event reporting and the analysis, interpretation of efficacy, safety, and outcomes data.

The MMS medical monitoring team adds value throughout the clinical trial process, including the evaluation and determination of the clinical implications of the study results.

Suggested For You

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

perspectives

November 26th, 2024

Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs 

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development